Labs / Assays & in vitro testing
Denteric
Malbourne, Australia · denteric.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Denteric develops therapies for diseases related to Porphyromonas gingivalis and chronic inflammation. Its lead program GPV381 is being developed initially for patients with severe or refractory periodontitis, with interest in other diseases including Alzheimer’s disease, diabetes, and cardiovascular disease. The company is based in Melbourne, Australia.
Their website has a general contact form; we send your quote request through it.
What they offer
GPV381 development
Develops GPV381, a novel therapy targeting gingipains from Porphyromonas gingivalis to treat chronic inflammation and periodontitis.
Porphyromonas gingivalis-related disease therapy development
Develops vaccines and therapies for diseases associated with Porphyromonas gingivalis.
What they work on
- Modalities
- Vaccine
- Therapeutic areas
- periodontitis, chronic inflammation, Alzheimer’s disease, diabetes, cardiovascular disease
- Sites
- Melbourne, Australia
Similar labs. JPT Peptide Technologies, 3C Therapeutics, Abeomics, Alphalyse
Found in a contract services directory. Listing built from denteric.com. Work here? Claim this listing.